Heart­burn: Iron­wood shares sink af­ter block­buster con­tender dis­ap­points on a key goal in PhI­Ib

Iron­wood Phar­ma­ceu­ti­cals $IR­WD CEO Pe­ter Hecht has some block­buster ex­pec­ta­tions for one of his top clin­i­cal can­di­dates. But he’s hav­ing a hard time con­vinc­ing an­a­lysts and in­vestors of that to­day af­ter rolling out a dis­ap­point­ing batch of top-line da­ta.

The biotech re­port­ed Thurs­day morn­ing that the high dose of its ex­per­i­men­tal drug — IW-3718 — for gas­troe­sophageal re­flux dis­ease (GERD) not con­trolled by avail­able meds hit the pri­ma­ry end­point on sig­nif­i­cant­ly re­duc­ing heart­burn sever­i­ty for pa­tients in a Phase IIb tri­al.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER